Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12592235.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The study was undertaken to determine whether metoclopramide pretreatment attenuates side effects associated with high-dose estrogen/progestin emergency contraception in at-risk patients. This was a randomized, prospective, double-blind, placebo-controlled study at the University of Kansas. Patients (141) requesting emergency contraception and lacking contraindications were offered entry in the study. Both the treatment (metoclopramide 10 mg) and placebo groups received active emergency contraception. Participants evaluated symptom severity with a 12-question survey tool developed for this study. Metoclopramide pretreatment provided protection against nausea and cramping associated with estrogen/progestin emergency contraception. The average scores on a 10-point scale for the treatment group and placebo group were as follows: nausea 3.2 versus 4.8 (P =.01) and cramping 0.9 versus 2.2 (P <.01), indicating less severe nausea and cramping in the treatment group. Metoclopramide pretreatment attenuates the nausea and cramping associated with Yuzpe emergency contraceptive treatment.
Medical subject headings
- Antiemetics
- Contraceptives, Oral, Combined
- Contraceptives, Postcoital
- Emergency Medical Services
- Estrogens
- Metoclopramide
- Nausea
- Progestins